CHAMPIONS extension: 10-year outcomes in interferon beta-1a-treated patients at high risk for developing multiple sclerosis after a clinically isolated syndrome

被引：0
|
作者：
Putzki, N. [1 ,2 ]
Kinkel, R. P. [3 ]
Dontchev, M. [4 ]
Tanner, J. P. [4 ]
Kollman, C. [4 ]
Simon, J. [5 ]
O'Connor, P. [6 ]
Hyde, R. [7 ]
机构：
[1] Cantonal Hosp, St Gallen, Switzerland
[2] Univ Duisburg Essen, Dept Neurol, Essen, Germany
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Hlth Res Fdn Inc, Jaeb Ctr, Tampa, FL USA
[5] Portland VA Med Ctr, Portland, OR USA
[6] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[7] Biogen Idec Inc, Cambridge, MA USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2009年 / 285卷
关键词：
D O I：
10.1016/S0022-510X(09)70475-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [1] CHAMPIONS: 10-year follow-up after a clinically isolated syndrome in patients at high risk for developing multiple sclerosis
    Kinkel, R. P.
    Dontchev, M.
    Tanner, J. P.
    Kollman, C.
    Simon, J.
    O'Connor, P. W.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S128 - S129
  • [2] CHAMPIONS Extension Study: 10 Year Follow-Up after a Clinically Isolated Syndrome (CIS) in High Risk Patients
    Kinkel, Revere
    Tanner, Jean Paul
    Simon, Jack
    O'Connor, Paul
    Kollman, Craig
    NEUROLOGY, 2009, 72 (11) : A315 - A316
  • [3] Long-term study of high-risk patients after a clinically isolated syndrome: 10-year follow-up from CHAMPIONS
    Kinkel, R. P.
    Simon, J.
    O'Connor, P. W.
    Kollman, C.
    JOURNAL OF NEUROLOGY, 2009, 256 : S10 - S10
  • [4] Intramuscular interferon-β-1a -: In patients at high risk of developing clinically definite multiple sclerosis
    Asif, M
    Siddiqui, A
    Wellington, K
    CNS DRUGS, 2005, 19 (01) : 55 - 61
  • [5] Intramuscular interferon-β-1a: In patients at high risk of developing clinically definite multiple sclerosis
    Siddiqui M.A.A.
    Wellington K.
    CNS Drugs, 2005, 19 (1) : 55 - 61
  • [6] Tolerability of Interferon Beta-1b for Multiple Sclerosis and Clinically Isolated Syndrome in Korea
    Seok, Hung Youl
    Kim, Byung-Jo
    Kim, Byoung Joon
    Oh, Jeeyoung
    Joo, In Soo
    Lim, Young-Min
    Kim, Kwang-Kuk
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 818 - 818
  • [7] Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis
    Di Legge, S
    Piattella, MC
    Pozzilli, C
    Pantano, P
    Caramia, F
    Pestalozza, IF
    Paolillo, A
    Lenzi, GL
    MULTIPLE SCLEROSIS JOURNAL, 2003, 9 (03) : 302 - 306
  • [8] Interferon beta-1a modulates the initiation of autoimmune response in patients with clinically isolated syndrome suggestive of multiple sclerosis
    Zhang, Xin
    Tang, Yunan
    Jin, Jianping
    Markovic-Plese, Silva
    NEUROLOGY, 2008, 70 (11) : A375 - A375
  • [9] Cost-utility of interferon beta-1b in the treatment of patients with a clinically isolated syndrome suggestive of multiple sclerosis
    Caloyeras, J. P.
    Wang, C.
    Bauer, L.
    Lee, W. C.
    Lanius, V
    Gondek, K.
    VALUE IN HEALTH, 2008, 11 (03) : A141 - A141
  • [10] Subcutaneous interferon beta-1a, 10-year results from the United Kingdom Multiple Sclerosis Risk Sharing Scheme
    Harty, G.
    Wong, S.
    Gillett, A.
    Davies, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 494 - 494
12345